The United States Government Accountability Office (GAO) has issued a report on the implementation of the Medicare drug pricing provisions of the Inflation Reduction Act of 2022.  GAO found that the Medicare drug pricing provisions had been implemented effectively and that plans for monitoring appropriated funds for the drug negotiation and inflation rebate programs are consistent with relevant federal internal control principles.  To read the GAO report on Medicare drug pricing, use the first link below.  To read GAO highlights of the report on Medicare drug pricing, use the second link below.

https://www.gao.gov/assets/gao-25-106996.pdf  (GAO report on Medicare drug pricing)

https://www.gao.gov/assets/gao-25-106996-highlights.pdf  (GAO highlights on Medicare drug pricing)